Shareholders Approve 3.5M Share Increase for Incentive Plan

summarizeSummary

DiaMedica Therapeutics shareholders approved an increase of 3.5 million shares for the company's equity incentive plan, alongside re-electing all incumbent directors and ratifying executive compensation.

check_boxKey Events

• Incentive Plan Share Increase Approved

  Shareholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing the number of shares available by 3,500,000. This represents a potential dilution of approximately 6.5% of current outstanding shares.

• Incumbent Directors Re-elected

  All seven incumbent directors were re-elected to the Board, maintaining the current leadership structure.

• Executive Compensation Approved

  The advisory (non-binding) vote to approve the company's executive compensation was passed.

• Auditor Ratified

  Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.

auto_awesomeAnalysis

DiaMedica Therapeutics shareholders approved an increase of 3.5 million shares for the company's equity incentive plan. This authorization represents a potential future dilution of approximately 6.5% based on current outstanding shares. While such plans are common for talent retention in life sciences, this increase comes as the company recently reported a wider net loss and increased cash burn, making any potential dilution more sensitive. The re-election of all incumbent directors maintains continuity in the company's governance.